<DOC>
	<DOCNO>NCT01073644</DOCNO>
	<brief_summary>The primary purpose monitor safety tolerability effectiveness sunitinib malate treatment patient metastatic renal cell carcinoma gastrointestinal stromal tumor among filipino patient usual clinical practice setting .</brief_summary>
	<brief_title>Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate ( Sutent ) For Filipino Patients</brief_title>
	<detailed_description>Open label</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Age 18 year Diagnosed metastatic renal cell carcinoma gastrointestinal stromal tumor imatinib treatment failure intolerance Subjects condition contraindicate sunitinib malate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>imatinib resistant intolerant</keyword>
</DOC>